

Knee Osteoarthritis: Overview of Current and Evolving Treatment

Michael Clayman, M.D., Guest Author

References

1. Wallace I, Worthington S, Felson D, Jurmain R, Wren K, Maijanen H, Woods R, Lieberman D. Knee osteoarthritis has doubled in prevalence since the mid-20th century. *PNAS* 2017;114 (35) 9332-933.
2. Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. *BMJ*. 2011;342:d1165.
3. Cisternas MG, Murphy L, Sacks JJ, Solomon DH, Pasta DJ, Helmick CG. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. *Arthritis Care Res*. 2016;68:574-580.
4. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: New insights. Part 1: The disease and its risk factors. *Ann Intern Med*. 2000;133(8):635-646.
5. QuintilesIMS / Pharmetrics Plus Database, 2015/2016 Study Period, Projected to the US Insured Population of 280 million.
6. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bull World Health Disord*. 2003;81:646-656.
7. Burbine SA, Weinstein AM, Reichmann WM, et al. Projecting the future public health impact of the trend toward earlier onset of knee osteoarthritis in the past 20 years. Paper presented at: the 2011 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting; November 4-9, 2011; Chicago, IL.
8. Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Insurer and out-of-pocket costs of osteoarthritis in the US. *Arthritis Rheum*. 2009;60:3546-3553.
9. Wen CP, Wai JPM, Tsai MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. *Lancet*, 2011;378:1244-1253.
10. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. *Circulation*, 2003;107:3109-3116.
11. Herbolzheimer F, Schaap LA, Edwards MH, et al. Physical activity patterns among older adults with and without knee osteoarthritis in six European countries. *Arthritis Care Res*. 2016;68(2):228-236.
12. Jüni P, Hari R, Rutjes AW, et al. Intra-articular corticosteroid for knee osteoarthritis. *Cochrane Database Syst Rev*. 2015 Oct 22.
13. da Costa BR, Hari R, Jüni P. Intra-articular corticosteroids for osteoarthritis of the knee. *JAMA*. 2016;316:2671-2672.
14. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. *J Rheumatol*. 2006;33:2271-2279.
15. Piva SR, Susko AM, Khoja SS, et al. Links between Osteoarthritis and Diabetes: Implications for Management from a Physical Activity Perspective. *Clin Geriatr Med*, 2015;31:67-87.
16. Hoffman TC, Maher CG, Briffa T, et al. Prescribing exercise interventions for patients with chronic conditions. *CMAJ*, 2016;188:510-118.
17. Centers for Disease Control and Prevention. Physical Activity for Arthritis. Available at <https://www.cdc.gov/arthritis/basics/physical-activity-overview.html>. Accessed June 28, 2017.
18. Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. *RMD Open*. 2015;1:e000077.
19. Hawker GA, Croxford R, Bierman AS, et al. Osteoarthritis-related difficulty walking and risk for diabetes complications. *Osteoarthritis Cartilage*. 2017;25:67-75.
20. Liu S-H, Waring ME, Eaton CB, Lapane KL. Association of objectively measured physical activity and metabolic syndrome among US adults with osteoarthritis. *Arthritis Care Res*. 2015;67:1371-1378.
21. Marks R. Obesity profiles with knee osteoarthritis: correlation with pain, disability, disease progression. *Obesity*. 2007;15:1867-1874.
22. Reijman M, Pols HAP, Bergink AP, et al. Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: The Rotterdam Study. *Ann Rheum Dis*. 2007;66:158-162.

23. Rogers MW, Wilder FV. The association of BMI and knee pain among persons with radiographic knee osteoarthritis: a cross-sectional study. *BMC Musculoskeletal Disorders*. 2008;9:163.
24. Sharma L, Cahue S, Song J, Hayes K, Pai Y-C, Dunlop D. Physical functioning over three years in knee osteoarthritis. *Arthritis Rheum*. 2003;48:3359-3370.
25. Leyland KM, Gates LS, Sanchez-Santos MT. Knee osteoarthritis and the risk of premature mortality in the community: an international individual patient level meta-analysis in 9889 subjects. *Osteoarthritis and Cartilage*, 25(1):S80-S81.
26. Hochberg MC. Mortality in osteoarthritis. *Clin Exp Rheumatol*, 2008;26(5 Suppl 51):S120-4.
27. Eymard F, Parsons C, Edwards MH, et al. Diabetes is a risk factor for knee osteoarthritis progression. *Osteoarthritis Cartilage*. 2015;23:851-859.
28. da Costa BR, Nüesch E, Kasteler R, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip (review). *Cochrane Database Syst Rev*. 2014, Issue 9.
29. Gore M, Tai K-S, Sadosky A, et al. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. *Pain Practice*, 2012;12:550-560.
30. Armstrong HF, Mountford WK. Increased prevalence in opioid prescription as a first line therapy in osteoarthritis. Poster presented at: ISPOR 22nd Annual International Meeting; 2017 May 20 - 24; Boston, MA.
31. Weinstein AM, Rome BN, Reichmann WM, et al. Estimating the Burden of Total Knee Replacement in the United States. *J Bone Joint Surg Am*. 2013 Mar 6; 95(5): 385-392.
32. Chang DS, Hsu E, Hottinger DG and Cohe SP. Anti-nerve growth factor in pain management: current evidence. *J Pain Res*. 2016;9:373-383.
33. National Institute of Health. ClinicalTrials.gov. A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin (AS902330) in Patients With Osteoarthritis of the Knee (FORWARD). EMDSerono.
34. National Institute of Health. ClinicalTrials.gov. A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects). Samumed LLC.
35. Stevens R, Petersen D, Ervin J, et al. Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study. Presented at 2017 ACR/ARHP Annual Meeting on September 18, 2017. Abstract number 1191.
36. Grol MW, Nixon A, Lang HM, et al. Interleukin-1 receptor antagonist gene therapy prevents and delays surgically-induced osteoarthritis in small and large animal models. Presented at 2018 World Congress on Osteoarthritis on April 29, 2018. Abstract number 85.